Buprenorphine telemedicine · federal source guide
Federal rules provide a defined telemedicine pathway for some buprenorphine treatment, but reporting must preserve its conditions and keep eligibility, prescribing and clinical decisions separate.
What the official Q&A describes
SAMHSA’s current Buprenorphine Telemedicine Prescribing Q&A explains a final DEA and HHS pathway for a practitioner who has not conducted an in-person visit with a patient. The agency describes audio-only and audio-visual encounters and a total six-month medication-supply limit under that method.
The Q&A also identifies conditions such as checking the prescription drug monitoring program for the state where the patient is located and documenting that check. After the six-month supply, the source says an in-person evaluation or another federally authorized telemedicine mechanism is required.
What this does not establish
The federal pathway does not decide whether buprenorphine is clinically appropriate for a particular person. It does not replace state law, professional licensure, a clinician’s assessment, pharmacy requirements or other applicable records and privacy rules.
Eligibility asks whether the pathway applies. Prescribing asks whether legal and documentation conditions are met. Clinical care asks what treatment is appropriate. None guarantees the next.
Production verification card
- Confirm the Q&A and linked final rule are still current.
- Record patient location and the applicable state sources.
- Preserve the encounter-method, monitoring and time-limit conditions.
- Do not translate federal permission into a prescription promise.
What patients can verify next
Patients seeking treatment can ask a qualified provider how current federal and state requirements apply and what evaluation is needed. This article offers no diagnosis, medication recommendation or dosing instruction. Urgent concerns require appropriate local clinical or emergency help.